Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-α blockers;Correlazione tra diversa attività clinica e titolo degli anticorpi anti peptide ciclico citrullinato in corso di terapia anti TNFα nell'artrite reumatoide

Recenti Progressi in Medicina

Volumn 97, Issue 3, 2006, Pages 134-139

  Benucci, Maurizio ^a   Turchini, Stefano ^b   Parrochi, Paola ^b   Boccaccini, Piero ^b   Manetti, Roberto ^b   Cammelli, Emanuela ^a   Manfredi, Mariangela ^a  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cyclic citrullinated peptide; Rheumatoid arthritis; Rheumatoid factor; TNF blocking agents

Indexed keywords

ACUTE PHASE PROTEIN; ADALIMUMAB; AUTOANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN M; INFLIXIMAB; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISABILITY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MALE; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646004315     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lipsky P, van der Heijde D, St Clair E, Furst D, Breedveld F, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis (ATTRACT study). N Eng J Med 2000; 343: 1594-602.
2. Weinblatt ME, Kremer JM, Bankhurst AD. A trial of etanercept, a recombinant tumor necrosis factor receptor/Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Eng J Med 1999; 340: 253-9.
3. Weinblatt M, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbera CA, Teoh LA. Adalimumab a fully human anti-tumor necrosis factor a monoclonal antibody for treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
4. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
5. Schellekens GA, Visser H, De Jong BA. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-63.
6. Masson-Bessiere C, Sabbag M, Girbal Neuhauser E. The major synovial targets of rheumatoid arthritis-specific antifilaggrin autoantibodies are deaminated form of alpha and beta chains of fibrin. J Immunol 2001; 166: 4177-84.
7. Goldbach-Mansky R, Lee J, McCoy A. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000; 2: 236-44.
8. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120-6.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid artrhitis. Arthritis Rheum 1988; 31: 315-24.
10. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
11. Benucci M, Del Rosso A, Turchini S, Parronchi P, Li Gobbi F, Fossi F, et al. In rheumatoid arthritis different tumor necrosis factor alpha blockers share clinical efficacy but have different effects on anti cyclic citrullinated peptide antibodies. Ann Rheum Dis 2005; 64: SIII 432.
12. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004; 6: 264-72.
13. De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM, De Keyser F. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 299-302.
14. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004; 63: 1218-21.
15. Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, et al. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 2005; 26: 58-62.
16. Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 35-39.
17. Yazdani-Biuki B, Stadlmaier E, Mulabecirovic A, Brezinschek R, Tilz G, Demel U, et al. Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1224-6.
18. Fu YX, Molina H, Matzumoto M, Huang G, Min J, Chaplin DD. Lymphotoxin alpha supports development of splenic follicular structure that is required for IgG responses. J Exp Med 1997; 185: 211-20.
19. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, Fraser A, Emery P. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2005; in corso di pubblicazione.